# A Study of IMP4297 in Patients With Advanced Solid Tumors

> **NCT03508011** · PHASE1 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Advanced Solid Tumours
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer

## Interventions

- **DRUG:** IMP4297

## Key facts

- **NCT ID:** NCT03508011
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2020-12-16
- **Final completion:** 2020-12-16
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03508011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03508011, "A Study of IMP4297 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03508011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*